Arun Rajaratnam1,2, Sofiya Rehman2, Prerna Sharma2, Vikas K Singh2, Melissa Saul2,3, Rebecca R Vanderpool1,4, Mark T Gladwin1,2,5, Marc A Simon1,2,4,6,7, Alison Morris1,2,5. 1. Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, United States of America. 2. Department of Medicine, University of Pittsburgh, Pittsburgh, PA United States of America. 3. Analytics Center, University of Pittsburgh, Pittsburgh, PA, United States of America. 4. Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, United States of America. 5. Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, United States of America. 6. Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, United States of America. 7. UPMC Heart and Vascular Institute, Pittsburgh, PA, United States of America.
Abstract
BACKGROUND: People living with human immunodeficiency virus (PLWH) are at risk of developing pulmonary hypertension (PH) and right ventricular (RV) dysfunction, but understanding of the relationship of RV function to afterload (RV-PA coupling) is limited. We evaluated the clinical and hemodynamic characteristics of human immunodeficiency virus (HIV)-associated PH. METHODS: We performed a retrospective review of patients with a diagnosis of HIV undergoing right heart catheterization (RHC) from 2000-2016 in a tertiary care center. Inclusion criteria were diagnosis of HIV, age ≥ 18 years and availability of RHC data. PH was classified as either pulmonary arterial hypertension (PAH; mean pulmonary arterial pressure [mPAP] ≥ 25mmHg with pulmonary artery wedge pressure [PAWP] ≤ 15mmHg) or pulmonary venous hypertension (PVH; mPAP ≥ 25mmHg with PAWP > 15). We collected demographics, CD4 cell count, HIV viral load, RHC and echocardiographic data. The single beat method was used to calculate RV-PA coupling from RHC. RESULTS: Sixty-two PLWH with a clinical likelihood for PH underwent RHC. Thirty-two (52%) met PH criteria (15 with PAH, 17 with PVH). Average time from diagnosis of HIV to diagnosis of PH was 11 years. Eleven of 15 individuals with PAH were on antiretroviral therapy (ART) while all 17 patients with PVH were on ART. Compared to PLWH without PH, those with PH had an increased likelihood of having a detectable HIV viral load and lower CD4 cell counts. PLWH with PAH or PVH had increased RV afterload with normal RV contractility, and preserved RV-PA coupling. CONCLUSION: PLWH with PH (PAH or PVH) were more likely to have a detectable HIV viral load and lower CD4 count at the time of RHC. PLWH with PAH or PVH had increased RV afterload, normal RV contractility, with preserved RV-PA coupling suggestive of an early onset, mild, and compensated form of PH. These results should be confirmed in larger studies.
BACKGROUND: People living with human immunodeficiency virus (PLWH) are at risk of developing pulmonary hypertension (PH) and right ventricular (RV) dysfunction, but understanding of the relationship of RV function to afterload (RV-PA coupling) is limited. We evaluated the clinical and hemodynamic characteristics of human immunodeficiency virus (HIV)-associated PH. METHODS: We performed a retrospective review of patients with a diagnosis of HIV undergoing right heart catheterization (RHC) from 2000-2016 in a tertiary care center. Inclusion criteria were diagnosis of HIV, age ≥ 18 years and availability of RHC data. PH was classified as either pulmonary arterial hypertension (PAH; mean pulmonary arterial pressure [mPAP] ≥ 25mmHg with pulmonary artery wedge pressure [PAWP] ≤ 15mmHg) or pulmonary venous hypertension (PVH; mPAP ≥ 25mmHg with PAWP > 15). We collected demographics, CD4 cell count, HIV viral load, RHC and echocardiographic data. The single beat method was used to calculate RV-PA coupling from RHC. RESULTS: Sixty-two PLWH with a clinical likelihood for PH underwent RHC. Thirty-two (52%) met PH criteria (15 with PAH, 17 with PVH). Average time from diagnosis of HIV to diagnosis of PH was 11 years. Eleven of 15 individuals with PAH were on antiretroviral therapy (ART) while all 17 patients with PVH were on ART. Compared to PLWH without PH, those with PH had an increased likelihood of having a detectable HIV viral load and lower CD4 cell counts. PLWH with PAH or PVH had increased RV afterload with normal RV contractility, and preserved RV-PA coupling. CONCLUSION: PLWH with PH (PAH or PVH) were more likely to have a detectable HIV viral load and lower CD4 count at the time of RHC. PLWH with PAH or PVH had increased RV afterload, normal RV contractility, with preserved RV-PA coupling suggestive of an early onset, mild, and compensated form of PH. These results should be confirmed in larger studies.
Authors: Khodr Tello; Manuel J Richter; Jens Axmann; Martin Buhmann; Werner Seeger; Robert Naeije; Hossein Ardeschir Ghofrani; Henning Gall Journal: Am J Respir Crit Care Med Date: 2018-09-15 Impact factor: 21.405
Authors: Raymond L Benza; Mardi Gomberg-Maitland; C Greg Elliott; Harrison W Farber; Aimee J Foreman; Adaani E Frost; Michael D McGoon; David J Pasta; Mona Selej; Charles D Burger; Robert P Frantz Journal: Chest Date: 2019-02-14 Impact factor: 9.410
Authors: Eric A Secemsky; Rebecca Scherzer; Elaine Nitta; Alan H B Wu; David C Lange; Steven G Deeks; Jeffrey N Martin; James Snider; Peter Ganz; Priscilla Y Hsue Journal: JACC Heart Fail Date: 2015-07-08 Impact factor: 12.035
Authors: Marc A Simon; Christopher D Lacomis; M Patricia George; Cathy Kessinger; Renee Weinman; Deborah McMahon; Mark T Gladwin; Hunter C Champion; Alison Morris Journal: J Card Fail Date: 2014-04-12 Impact factor: 5.712
Authors: Rebecca R Vanderpool; Reena Puri; Alexandra Osorio; Kelly Wickstrom; Ankit Desai; Stephen Black; Joe G N Garcia; Jason Yuan; Franz Rischard Journal: Pulm Circ Date: 2019-04-29 Impact factor: 3.017
Authors: Valerie J Rodriguez-Irizarry; Alina C Schneider; Daniel Ahle; Justin M Smith; Edu B Suarez-Martinez; Ethan A Salazar; Brianyell McDaniel Mims; Fahmida Rasha; Hanna Moussa; Naima Moustaïd-Moussa; Kevin Pruitt; Marcelo Fonseca; Mauricio Henriquez; Matthias A Clauss; Matthew B Grisham; Sharilyn Almodovar Journal: Front Immunol Date: 2022-08-05 Impact factor: 8.786